BackShanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd. Overview

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd. Receivables

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd.'s receivables is $260M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$261.25M
↓ 28.95% YoYΔ $-106.43M vs prior year quarter

Peer trimmed avg / median

Loading

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd. Receivables History

Loading

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd. vs. peers: Receivables Comparison

Loading

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd. Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd. (688505.SS) FAQ

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd. posts a receivables of $260M as of September 2026. That compares with $370M in the prior-year period — down 28.9% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd.'s receivables was $370M. The latest reading is $260M — a 28.9% year-over-year decrease (period ending September 2026). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd.'s financial statement story. At $260M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for 688505.SS's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd.'s other metric pages and overview cover the third.